SouthState Corp Has $1.79 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

SouthState Corp raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 7,341 shares of the medical instruments supplier’s stock after acquiring an additional 72 shares during the period. SouthState Corp’s holdings in Becton, Dickinson and Company were worth $1,790,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in BDX. OFI Invest Asset Management bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. DiNuzzo Private Wealth Inc. acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $30,000. Fortitude Family Office LLC bought a new position in Becton, Dickinson and Company during the fourth quarter worth about $35,000. Venturi Wealth Management LLC increased its position in Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 138 shares during the last quarter. Finally, Arlington Trust Co LLC bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $41,000. 86.97% of the stock is owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded down $5.73 during trading on Friday, reaching $234.62. 1,722,348 shares of the stock were exchanged, compared to its average volume of 1,413,846. The stock has a 50-day moving average price of $238.68 and a 200-day moving average price of $240.71. The firm has a market cap of $67.78 billion, a PE ratio of 55.61, a PEG ratio of 1.93 and a beta of 0.45. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the prior year, the business posted $2.86 earnings per share. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. Research analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is 90.05%.

Analysts Set New Price Targets

Separately, Barclays lifted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.